Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay202015	Fate Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO , May 20, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the pricing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Pricing of Public Offering of Common Stock 148.1 KB
Toggle SummaryMay182015	Fate Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO , May 18, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that it has commenced an underwritten public Read All »	View HTML Fate Therapeutics Announces Proposed Public Offering of Common Stock 20.8 KB
Toggle SummaryMay072015	Fate Therapeutics Reports First Quarter 2015 Financial Results Strategic Research Collaboration Established with Juno Therapeutics to Apply Small Molecule Modulators for Programming CAR and TCR Immunotherapies Additional Data from Ongoing Phase 2 PUMA Study of PROHEMA® Continue to Demonstrate Acceleration of, and Increased Incidence of Early, Neutrophil Read All »	View HTML Fate Therapeutics Reports First Quarter 2015 Financial Results 30.9 KB
Toggle SummaryMay062015	Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies Alliance Utilizes Fate's Hematopoietic Cell Programming Platform to Identify Small Molecule Modulators for Juno's Leading Genetically-Engineered T Cell Immunotherapies Read All »	View HTML Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies 27.1 KB
Toggle SummaryMay042015	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2015 Financial Results on May 7, 2015 SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a conference call and live Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2015 Financial Results on May 7, 2015 10.8 KB
Toggle SummaryApr292015	Fate Therapeutics to Present at Deutsche Bank 40th Annual Health Care Conference SAN DIEGO, April 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at Deutsche Bank 40th Annual Health Care Conference 10.5 KB
Toggle SummaryApr082015	Fate Therapeutics to Present at 14th Annual Needham Healthcare Conference SAN DIEGO, April 8, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at 14th Annual Needham Healthcare Conference 10.5 KB
Toggle SummaryMar182015	Fate Therapeutics to Present at the Regen Med Investor Day SAN DIEGO, March 18, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at the Regen Med Investor Day 10.5 KB
Toggle SummaryMar122015	Fate Therapeutics Reports Year-End 2014 Financial Results Favorable Phase 2 Interim Data From Ongoing PUMA Study of PROHEMA® in Adult Hematologic Malignancies Reported in December 2014 PROHEMA Clinical Data in Pediatric Hematologic Malignancies and Rare Genetic Disorders Expected in 2015 IND for Programmed Mobilized Peripheral Blood Candidate Using Read All »	View HTML Fate Therapeutics Reports Year-End 2014 Financial Results 34.8 KB
Toggle SummaryMar052015	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2014 Financial Results on March 12, 2015 SAN DIEGO, March 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a conference call and Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2014 Financial Results on March 12, 2015 10.5 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.